David Solomon's career from academia to VC to CEO highlights a key formula for biotech leadership: combining a disciplined, scientific approach with savvy corporate finance to effectively translate good science into innovative medicines for patients.

Kevin Pojasek credits his effectiveness to a deliberate 12-year journey through diverse roles—investing, company creation, research, and clinical operations. This broad experience allows a leader to understand how all parts of the company, from high-level strategy to detailed science, fit together.

Starting in business development at a large firm like Genentech provides a holistic understanding of the entire drug lifecycle—from discovery and regulation to clinical trials and marketing. This "full spectrum" view offers invaluable training for a future CEO.

Fundraising isn't a unique skill; it's a direct application of enterprise sales principles. Founders with a sales background have a significant advantage because they can apply the same tactics of pipeline management, relationship building, and closing to secure investment.

Luba Greenwood argues that unlike in tech, many biotech CEOs lack P&L experience. In today's cash-constrained market, CEOs need to be able to build financial models and understand finance deeply to be effective, a skill she personally developed after transitioning from law and science.

Investor preference for CEOs has shifted dramatically. While 2019-2021 favored scientific founder-CEOs, today’s tough market demands leaders with prior CEO experience. The ideal candidate has a "matrix organization" background, understanding all business functions, not just the science.

Despite experiences in biotech consulting and venture capital, CEO Andrew Obenshain cites his time as a primary care sales rep for Merck as his most formative job. This ground-level role provided an unparalleled understanding of the sales, marketing, and operational realities of the pharmaceutical industry, setting the foundation for his executive career.

Kenai CEO Nick Manusos attributes his startup success to his varied background at Abbott Labs, moving from manufacturing to sales to BD. This breadth prepared him to handle the multifaceted demands of a startup, where a leader must be a generalist who is comfortable with constant change.

Biotech CEOs with business-only backgrounds often possess a crucial humility about their scientific limitations. This forces them to prioritize hiring exceptional R&D talent and empowering them to succeed, avoiding the trap of micromanagement.